Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-1055a in Relapsed or Refractory Solid Tumors
NCT04419532Phase 1Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2020
- Primary completion
- Jul 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of DS-1055a in solid tumor, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Number of participants with dose-limiting toxicities at 21 days and Number of participants with adverse events at 3 years. Started Oct 2020; status: active, not recruiting.
02
Drugs
DS-1055a
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04419532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04419532.